Patents Examined by Matthew P Coughlin
  • Patent number: 11952327
    Abstract: In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are ?-allyl Knoevenagel adducts or quasi ?-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise ?-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: April 9, 2024
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Alexander James Grenning
  • Patent number: 11945808
    Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: April 2, 2024
    Assignee: Dart Neuroscience, LLC
    Inventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
  • Patent number: 11938127
    Abstract: Pharmaceutical compositions are provided according to aspects of the present disclosure which include a compound having chemical structural formula I: where R1 is selected from the group consisting of: an alkyl group, a heteroalkyl group, an aryl group, a heteroaryl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, a cycloalkyl group, a hetercycloalkyl group, an alkylcycloalkyl group, a heteroalkyl cycloalkyl group, an aralkyl group, a heteroaralkyl group, an alkoxy group, a polar group, an ester and a charged group; a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a pharmaceutically acceptable salt thereof; where R4? is H or an alkoxy group; where both R5 and R3? are OH, or where one or both OH groups is optionally modified as a pharmaceutically acceptable hydrolysable, or enzymatically cleavable, prodrug form thereof; and/or a deuterated form thereof; and/or a pharmaceutically acceptable salt thereof; and a pharma
    Type: Grant
    Filed: September 28, 2022
    Date of Patent: March 26, 2024
    Assignee: Wayne State University
    Inventor: Manohar Ratnam
  • Patent number: 11926540
    Abstract: A method for the oxidation of ethylene to form ethylene oxide which comprises treating an aqueous stream in a cycle water treatment unit containing an anion exchange resin to reduce the content of the impurities.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: March 12, 2024
    Assignee: Scientific Design Company, Inc.
    Inventors: Saurabh Katiyar, Saurabh H. Parikh, Jason P. Durand
  • Patent number: 11926612
    Abstract: This disclosure is directed to agonists of the apelin receptor (APJ) with heterocyclic cores and uses of such agonists.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: March 12, 2024
    Assignee: RESEARCH TRIANGLE INSTITUTE
    Inventors: Scott P. Runyon, Rangan Maitra, Sanju Narayanan, Kenneth S. Rehder
  • Patent number: 11919887
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: March 5, 2024
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia M. Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Patent number: 11912665
    Abstract: A 4-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)butanoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 25, 2023
    Date of Patent: February 27, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11912680
    Abstract: Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (II), or Formula (III) and methods of using a compound of Formula (I), Formula (II), or Formula (III), e.g., in the treatment of a mental health disease or disorder.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: February 27, 2024
    Assignee: EmpathBio, Inc.
    Inventors: Robert B. Perni, Glenn Short, Tanweer A. Khan
  • Patent number: 11905269
    Abstract: The invention provides a material comprising (i) a crown ether of formula (I), (ii) a crown ether of formula (II), and/or (iii) a crown ether of formula (III), or a salt thereof, wherein each m independently is an integer from 1 to 8, p is an integer from 1 to 1000, each “” designates an optionally present bond and/or structure, each X is an optionally present substituent, each * independently represents —H, ?O, or a bond to a remainder of the material, provided that at least one * is a bond to the remainder of the material, and wherein the remainder of the material is bound via a sp3-sp3 carbon-carbon bond, a method of making the material, and a method of using the material.
    Type: Grant
    Filed: November 4, 2022
    Date of Patent: February 20, 2024
    Assignee: Pall Corporation
    Inventors: Andrew Kocen, Yiren Zhang, Rehanah Sejoubsari, Ahmad Arabi Shams Abadi
  • Patent number: 11905263
    Abstract: A 4-nitro-N?-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: February 20, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11891382
    Abstract: The present invention provides processes for preparing a compound of formula (I) and pharmaceutically acceptable salts thereof, comprising deprotecting a compound of formula (II), wherein each R3 independently represents a tertiary alkyl group, preferably wherein each R3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula (I) and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula (I) and their use in the treatment of proliferative disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: February 6, 2024
    Inventors: Gregor Welti, Markus Heubes, David Tagliaferri
  • Patent number: 11866402
    Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: January 9, 2024
    Assignee: Corsair Pharma, Inc.
    Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
  • Patent number: 11858879
    Abstract: Provided herein are, inter alia, compounds inhibiting poly(ADP-ribose) Glycohydrolase (PARG) in a cancer cell and methods of treating cancer using compounds of the invention.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: January 2, 2024
    Assignee: CITY OF HOPE
    Inventors: Xiaochun Yu, Shih-Hsun Chen, Yate-Ching Yuan, Hongzhi Li, David Horne
  • Patent number: 11858916
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 2, 2024
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Patent number: 11851425
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: December 26, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Patent number: 11834404
    Abstract: The disclosure provides chemical compounds possessing therapeutic and/or protective properties against oxidative damage. Methods of making such therapeutic and/or protective compounds and associated compositions are also provided, as are methods for their use, which include protecting cells from oxidative damage and/or inhibiting production of ROS in a cell or subject, as well as preventing or reducing the extent of tissue damage caused by an ischemic event in a subject at elevated risk of such an event.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: December 5, 2023
    Assignee: University of South Alabama
    Inventors: Gary Piazza, Xi Chen, Herbert Weissbach, Shailaja Kesraju Allani
  • Patent number: 11834441
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: December 5, 2023
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Steven John Durrant, Nadia Ahmad, Elizabeth Mary Beck, Lidio Marx Carvalho Meireles, Ewa Iwona Chudyk, Gorka Etxebarria Jardi, Bhairavi Galan, Sara S. Hadida Ruah, Dennis James Hurley, Ronald Marcellus Knegtel, Timothy Donald Neubert, Joanne Louise Pinder, Joseph Pontillo, Robert Pullin, Yvonne Schmidt, David Matthew Shaw, Sarah Skerratt, Dean Stamos, Stephen Andrew Thomson, Anisa Nizarali Virani, Christopher Wray
  • Patent number: 11826426
    Abstract: Metal-organic layers (MOLs) and metal-organic nanoplates (MOPs) comprising photosensitizers are described. The MOLs and MOPs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOL or MOP. Also described are methods of using MOLs and MOPs in photodynamic therapy, X-ray induced photodynamic therapy (X-PDT), radiotherapy (RT), radiodynamic therapy, or in radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: November 28, 2023
    Assignee: The University of Chicago
    Inventors: Wenbin Lin, Kaiyuan Ni, Guangxu Lan
  • Patent number: 11827611
    Abstract: The present invention relates to a ubiquitin-specific peptidase 24 inhibitor, a medicinal composition including the same and a method of delaying or reversing multidrug resistance in cancers using the same. The USP24 inhibitor, which includes a shUSP24 RNA and/or a carbonyl substituted phenyl compound, can serve as a chemosensitizing agent for inhibiting the drug pump out, cancer sternness and genomic instability of cancer cells, thereby being applied to a medicinal composition and a method for delaying or reversing multidrug resistance in cancers.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: November 28, 2023
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Chien-Chung Hung, Ming-Jer Young
  • Patent number: 11807603
    Abstract: The invention relates to a polyglycerol partial ester obtainable by esterification of a polyglycerol with a carboxylic acid mixture comprising at least one polyhydroxycarboxylic acid of a hydroxycarboxylic acid having 8 to 32 carbon atoms, at least one short-chain dicarboxylic acid having 2 to 16, preferably 6 to 14, particularly preferably 8 to 12, carbon atoms, at least one long-chain dicarboxylic acid having 24 to 44, preferably 30 to 40, particularly preferably 34 to 38, carbon atoms, and at least one fatty acid selected from linear, unsaturated and branched, saturated fatty acids having 14 to 24 carbon atoms, to a method for preparing polyglycerol partial esters, and to the use of corresponding polyglycerol partial esters as W/O emulsifier.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: November 7, 2023
    Assignee: Evonik Operations GmbH
    Inventors: Jan Marian Von Hof, Achim Friedrich, Wolfgang Berkels, Barbara Hohenberg, Oliver Springer, Juergen Meyer